Disease relevance of Genital Neoplasms, Female

• Fasting calcium excretion, renal phosphorus threshold, plasma 1,25 dihydroxyvitamin D, immunoreactive PTH, nephrogenous cyclic AMP excretion, and tumor burden were assessed in nine patients with gynecologic neoplasms and hypercalcemia [1].

High impact information on Genital Neoplasms, Female

• Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up [2].
• Serum assays for CA 125 are often used in the diagnosis and follow-up of patients with gynecologic neoplasms [3].
• These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm [4].
• Ifosfamide exhibits promising activity in a variety of gynecologic neoplasms [5].
• Recently estrogen receptors have been identified in gynecologic neoplasms [6].

Chemical compound and disease context of Genital Neoplasms, Female

• Photodynamic therapy of gynecologic neoplasms after presensitization with hematoporphyrin derivative [7].
• Sex steroid receptors in gynecologic neoplasms [8].
• A study of cytoplasmic and nuclear estrogen and progestin receptors in gynecologic neoplasms [9].

Gene context of Genital Neoplasms, Female

• Tumor and serum CEA content in gynecologic neoplasms [10].
• Immunohistochemical and ultrastructural investigation of new membrane-associated placental tissue proteins (MP2 A, B, C, D, and E) in gynecologic neoplasms [11].

References